重组人白介素-11对血液肿瘤化疗后血小板减少恢复的效果

Efficacy evaluation of recombinant human interleukin-11 on thrombocytopenia in patients with hematologic cancers after chemotherapy

目的:观察重组人白细胞介素-11(rHuIL-11)防治血液肿瘤化疗后血小板减少症的疗效和不良反应。方法:应用自身对照方法,对21例血液肿瘤第1周期(对照期)单用化疗、第2周期(观察期)化疗后加用rHuIL-11,观察血小板变化及不良反应。结果:观察期血小板最低值高于对照期[(49.2±20.8)×109/L∶(24.5±15.8)×109/L,P<0.01],血小板<15×109/L持续天数少于对照期[(0.54±1.45)d∶(2.46±2.54)d,P<0.01],血小板<50×109/L持续天数少于对照期[(2.08±2.66)d∶(6.38±3.43)d,P<0.01],5例有轻度不良反应,表现为头痛及头晕、骨骼及关节疼痛、乏力、发热、谷丙转氨酶升高。结论:rHuIL-11防治血液肿瘤化疗后血小板减少症疗效肯定,不良反应可耐受。

Objective：To observe the efficacy and side effects of recombinant human interleukin-11 in the treatment of thrombocytopema in patients with hematologic cancers being given chemotherapy. Method.21 patients （4 with acute myeloblastic leukemia, 2 with acute lymphocytic leukemia, 9 with non-Hodgkin lymphoma and 6 with multiple myeloma） were not given rHulL-11 after chemotherapy in the first cycle while given rHulL-11 after chemotherapy in the second cycle. The changes of platelet in the peripheral blood and side effects were observed. Result：The lowest value of platelet was higher in the second cycle than in the first cycle [（49.2±20.8） × 10^9/L VS （24.5±15.8）× 10^9/L, P 〈0.01], while the lasting days of platelet value 〈15 × 10^9/L in the second cycle was shorter than in the first cycle [（0.54±1.45） d VS （2.46±2.54） d, P 〈0.01] and the lasting days of platelet value 〈50× 10^9/L in the second cycle was shorter than in the first cycle [（2.08±2.66） d VS （6.38±3.43） d, P 〈0.01]. 5 patients had slight side effects such as headache, fatigue and slight fever etc. Conclusion：Recombinant human interleukin-11 is effective and safe in the treatment of thrombocytopenia in patients with hematologic cancers being given chemotherapy.